Azurity Pharmaceuticals
As of the edition of 20 October 2026, Azurity Pharmaceuticals runs 38 drugs, 38 of them marketed; it is on route A at 0 targets and on route B at 15 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 38 |
| Total | 38 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Methotrexate | none listed | 2 |
| Mycophenolate mofetil | none listed | 1 |
| Amlodipine | none listed | 16 |
| Bendamustine | Ends 2029 (patent) | 0 |
| Omeprazole | none listed | 2 |
| Sitagliptin | Ends 2026 (patent) | 1 |
| Testosterone | none listed | 4 |
| Topiramate | none listed | 25 |
| Vancomycin | none listed | 0 |
| Carmustine | none listed | 1 |
| Digoxin | none listed | 0 |
| Nilotinib | Ends 2032 (patent) | 0 |
| Clonidine | none listed | 0 |
| Aprepitant | none listed | 2 |
| Triptorelin | none listed | 0 |
| Meloxicam | none listed | 1 |
| Ferumoxytol | Ends 2028 (exclusivity) | 0 |
| Lomustine | none listed | 0 |
| Lisdexamfetamine | none listed | 6 |
| Lisinopril anhydrous | none listed | 1 |
| Verapamil | none listed | 8 |
| Baclofen | none listed | 1 |
| Riluzole | none listed | 9 |
| Sumatriptan | none listed | 1 |
| Enalapril | none listed | 3 |
A route B row is one company at one target. 13 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 0 targets, route B at 15 targets.
All 15 rows on route A or B
In the product15 company-target rows on route A or B; 12 are not shown here, and no score is.
See all 15 targets where Azurity Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.